SCHEMBL1932041

SCHEMBL1932041

COc1cccc(-c2nc(C(=O)c3ccc([N+](=O)[O-])c(OC)c3)n3ccccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 7/20 0.41
▸ MAPT P10636 6/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ PPARG P37231 1/20 0.37
▸ EIF4E P06730 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ABCB1 P08183 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1930756 0.91 RORC (0.45) RORCMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1932592 0.85 MAPT (0.45) RORCMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1931410 0.83 ALDH1A1 (0.42) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL1931663 0.82 MAPK1 (0.43) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL1931559 0.82 ALDH1A1 (0.40) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL2711607 0.81 RORC (0.37) RORCMAPTSMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL1931669 0.81 MAPK1 (0.42) MAPTNPC1RAB9AALDH1A1KMT2A
SCHEMBL1931390 0.81 ALDH1A1 (0.40) MAPTSMN1; SMN2ALDH1A1KMT2AABCB1
SCHEMBL1930915 0.80 ALDH1A1 (0.41) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL1930678 0.79 ALDH1A1 (0.40) MAPTSMN1; SMN2ALDH1A1KMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633216-B2 Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI (FR) 2014-01-21 — — US disclosed
EP-1861403-B1 NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SA (FR) 2012-05-02 — — EP disclosed
US-8008321-B2 Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications SANOFI-AVENTIS (FR) 2011-08-30 — — US disclosed
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2011-06-09 — — US disclosed
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same CYP3A5, CYP4B1, CYP3A7 RORC 279/4885MAPT 2878/4885SMN1; SMN2 2463/4885
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same P2RX6, IL5, ATIC RORC 464/4885MAPT 2116/4885SMN1; SMN2 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback